# 8. Behavioral & Case Studies

Research direction decisions, collaboration across the ML-research/biology divide, and how you handle the genuine ambiguity of foundation model research.

---

### Q: Tell me about a time a research direction you were pursuing turned out to be a dead end, or produced a negative/null result. How did you handle it? 🟡

**What a strong answer includes:**
- Honesty that this is a normal, expected part of foundation model research — interviewers are wary of candidates who present every project as a clean success story, since real research (especially in a fast-moving, exploratory field) frequently involves dead ends.
- A specific account of how you determined the direction wasn't working — ideally through a well-designed experiment or ablation that gave a genuinely informative negative result, rather than vague discouragement.
- Evidence you extracted useful learning from the negative result (e.g., it informed a better-directed next attempt, or was itself a useful finding worth documenting/sharing internally) rather than treating it as pure wasted effort.
- An honest account of how you communicated this to collaborators/leadership, especially if it meant reallocating significant compute/time investment away from the original direction.

**Follow-ups:**
- How did you decide when it was time to stop pursuing that direction, versus continuing to iterate on it further?

---

### Q: Describe a time you had to decide between pursuing a more ambitious, higher-risk research idea versus a safer, more incremental one, given limited time/compute budget. 🟡

**What a strong answer includes:**
- A clear, specific articulation of the actual tradeoff considered (expected scientific value, probability of success, compute/time cost, how the result would be used) rather than a purely instinctive preference for ambition or safety.
- Evidence of a structured approach to reducing risk on the ambitious idea before fully committing (e.g., a smaller-scale pilot experiment to test the core hypothesis cheaply before committing to a full-scale, expensive version) rather than an all-or-nothing bet.
- An honest account of the outcome and, ideally, reflection on whether the decision was right in hindsight, including if the ambitious idea didn't pan out as hoped.

**Follow-ups:**
- How do you personally calibrate how much of your research portfolio (or a team's) should go toward high-risk, high-reward ideas versus safer, incremental progress?

---

### Q: Walk me through how you'd approach a new research collaboration with a wet-lab or experimental biology team who wants your foundation model's predictions validated experimentally. 🟡

**Case-study structure — a strong candidate would:**
1. **Clarify the specific scientific question and what a genuinely informative experimental validation would look like** — not just "test the model," but a clearly specified, falsifiable comparison (e.g., a specific set of model predictions the experimental team will independently test, agreed upon before seeing results, to avoid the researcher-degrees-of-freedom concerns discussed in section 7).
2. **Set realistic, well-calibrated expectations about the model's likely performance and known limitations** upfront, rather than overselling the model's capabilities to secure the collaboration, since an experimental team investing real wet-lab resources deserves an honest assessment of the model's actual, current state of validation.
3. **Design the experimental validation to be maximally informative** even in the case of a negative result — e.g., choosing predictions that span a range of the model's confidence levels, so a validation experiment can inform not just "does the model work" but "how does model confidence relate to actual experimental success," which is more scientifically valuable than a single pass/fail test.
4. **Plan for how results (positive or negative) will feed back into future model development**, closing the loop rather than treating the validation as a one-off, standalone checkpoint disconnected from ongoing research.

**Follow-ups:**
- The experimental validation comes back with mixed results — some predictions confirmed, others not. How would you approach interpreting and communicating this nuanced outcome to both the experimental collaborators and your own research leadership?

---

### Q: Tell me about a time you disagreed with a collaborator (ML researcher or biologist) about whether a model's apparent improvement was scientifically meaningful versus a benchmark artifact. 🔴

**What a strong answer includes:**
- A specific, technically grounded disagreement (e.g., about evolutionary redundancy/leakage, researcher degrees of freedom, or benchmark saturation, connecting to sections 3, 4, and 7) rather than a vague interpersonal conflict.
- Evidence of resolving the disagreement through additional evidence/experiments (e.g., re-running the evaluation under a more rigorous protocol, or checking against an independent benchmark) rather than through seniority or persistence alone.
- A clear account of what was ultimately concluded and how this affected the direction of the work or what was reported/published, including situations where you were wrong and updated your own view based on the additional evidence.

**Follow-ups:**
- How do you personally maintain healthy skepticism about your own team's positive results, given the natural incentive to want your own research to show a favorable outcome?

---

### Q: Describe a situation where you had to communicate a foundation model's genuine limitations to a stakeholder (e.g., a product team, a business partner, or non-ML-research leadership) who was hoping for a more capable or ready-to-deploy result. 🟡

**What a strong answer includes:**
- A specific example of translating a genuine research-stage limitation (e.g., "this model performs well on well-represented protein families but hasn't been validated on X," or "this is a promising research direction but is not yet validated to production-reliability standards") into terms the stakeholder could use to make a good decision, rather than either overselling research-stage results or being so hedged as to be unhelpful.
- Evidence of proactively flagging the gap between research-stage results and production-readiness (a distinction closely related to the retrospective-vs-prospective validation discussions in the AI Drug Discovery Scientist and Computational Biologist companion repos) before it became a problem, rather than only after a stakeholder was surprised by unmet expectations.
- A concrete, positive outcome showing the stakeholder was able to plan and make decisions appropriately as a result of your honest framing.

**Follow-ups:**
- How do you handle organizational pressure to overstate a research result's readiness/maturity for a business or fundraising narrative, while maintaining scientific integrity?

---

### Q: Tell me about a time you had to quickly get up to speed on an unfamiliar area (either a new biological domain, or a new ML technique) to make progress on a research project. 🟡

**What a strong answer includes:**
- A specific, systematic approach to rapidly building sufficient working knowledge (e.g., identifying and reading key foundational papers/reviews first, finding a knowledgeable collaborator to consult with, or running small exploratory experiments to build intuition) rather than either avoiding the unfamiliar area or proceeding without adequate understanding.
- Evidence of appropriately calibrating confidence in your own understanding — being willing to ask questions or seek expert review rather than overconfidently proceeding based on an incomplete understanding of a new domain.
- A concrete outcome demonstrating the new knowledge was successfully applied to make genuine research progress.

**Follow-ups:**
- How do you decide when you've learned enough about a new domain to proceed confidently with a research project, versus needing to invest more time in building foundational understanding first?
